[go: up one dir, main page]

AR076668A1 - Anticuerpos especificos para dkk-1 y sus usos - Google Patents

Anticuerpos especificos para dkk-1 y sus usos

Info

Publication number
AR076668A1
AR076668A1 ARP100101589A ARP100101589A AR076668A1 AR 076668 A1 AR076668 A1 AR 076668A1 AR P100101589 A ARP100101589 A AR P100101589A AR P100101589 A ARP100101589 A AR P100101589A AR 076668 A1 AR076668 A1 AR 076668A1
Authority
AR
Argentina
Prior art keywords
fragments
dkk
antibodies
procedures
bone
Prior art date
Application number
ARP100101589A
Other languages
English (en)
Original Assignee
Pfizer
Rinat Neuroscience Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Rinat Neuroscience Corp filed Critical Pfizer
Publication of AR076668A1 publication Critical patent/AR076668A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Anticuerpos y fragmentos de los mismos que se unen a Dkk-1 y, en particular, anticuerpos humanizados y fragmentos de los mismos que se unen a Dkk-1, anticuerpos completamente humanizados y fragmentos inmunologicamente funcionales que se unen a Dkk-1. También se proporcionan anticuerpos y fragmentos de los mismos que compiten con la union de un anticuerpo monoclonal anti-Dkk-1 de raton por la union a células Dkk-1+. También se proporcionan ácidos nucleicos que codifican anticuerpos anti-Dkk-1 o fragmentos de los mismos, así como vectores de expresion y células huésped que incorporan estos ácidos nucleicos para la expresion recombinante de anticuerpos anti-Dkk-1 y fragmentos de los mismos. También se proporcionan procedimientos para preparar los anticuerpos y fragmentos de los mismos. También se proporcionan agentes anabolizantes oseos. También se proporcionan composiciones farmacéuticas que comprenden los anticuerpos o fragmentos de los mismos. Se proporcionan además procedimientos para tratar enfermedades, afecciones y trastornos tales como trastornos oseos, que dan como resultado una pérdida de hueso. También se proporcionan procedimientos para tratar o prevenir una pérdida de masa osea, procedimientos para inducir masa osea aumentada y procedimientos para inducir actividad Wnt.
ARP100101589A 2009-05-12 2010-05-10 Anticuerpos especificos para dkk-1 y sus usos AR076668A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17765009P 2009-05-12 2009-05-12
US24463809P 2009-09-22 2009-09-22

Publications (1)

Publication Number Publication Date
AR076668A1 true AR076668A1 (es) 2011-06-29

Family

ID=42315893

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101589A AR076668A1 (es) 2009-05-12 2010-05-10 Anticuerpos especificos para dkk-1 y sus usos

Country Status (20)

Country Link
US (2) US8338576B2 (es)
EP (1) EP2430048A1 (es)
JP (1) JP2012526542A (es)
KR (1) KR101471239B1 (es)
CN (1) CN102666584A (es)
AR (1) AR076668A1 (es)
AU (1) AU2010246981B2 (es)
BR (1) BRPI1010540A2 (es)
CA (1) CA2761696A1 (es)
CO (1) CO6460768A2 (es)
IL (1) IL216304A0 (es)
MX (1) MX2011012039A (es)
NZ (1) NZ596274A (es)
PE (1) PE20120475A1 (es)
RU (1) RU2548817C2 (es)
SA (1) SA110310369B1 (es)
SG (1) SG175881A1 (es)
TW (1) TWI411444B (es)
WO (1) WO2010131185A1 (es)
ZA (1) ZA201108310B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101925611A (zh) * 2007-11-21 2010-12-22 安姆根有限公司 Wise结合剂和表位
AR083740A1 (es) * 2010-10-27 2013-03-20 Amgen Inc Anticuerpos dkk1 (dickkopf-1) y metodos de uso
US20120189633A1 (en) 2011-01-26 2012-07-26 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
WO2012154983A2 (en) 2011-05-10 2012-11-15 Biocare Medical, Llc Systems and methods for anti-pax8 antibodies
US10316103B1 (en) 2012-03-30 2019-06-11 Biocare Medical, Llc Systems and methods for anti-Uroplakin III antibodies
NZ630363A (en) * 2012-07-25 2018-09-28 Celldex Therapeutics Inc Anti-kit antibodies and uses thereof
US9429577B2 (en) 2012-09-27 2016-08-30 Biocare Medical, Llc Anti-uroplakin II antibodies systems and methods
US10429390B2 (en) 2012-12-18 2019-10-01 Biocare Medical, Llc Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
DK2962113T3 (da) 2013-02-28 2019-07-01 Biocare Medical Llc Systemer og fremgangsmåder med anti-p40-antistoffer
GB201312638D0 (en) * 2013-07-15 2013-08-28 King S College London Biomarkers
DK3052522T3 (da) 2013-10-03 2020-02-24 Biocare Medical Llc Anti-sox 10 antistofsystemer og -fremgangsmåder
EP3145543A4 (en) 2014-05-23 2017-12-13 Celldex Therapeutics, Inc. Treatment of eosinophil or mast cell related disorders
CA2981115C (en) 2015-05-18 2022-05-31 Eli Lilly And Company Anti-dkk-1-anti-rankl bispecific antibody compounds
WO2019098212A1 (en) 2017-11-14 2019-05-23 Chugai Seiyaku Kabushiki Kaisha Anti-c1s antibodies and methods of use
WO2019213285A1 (en) * 2018-05-02 2019-11-07 Ortheus, Inc. Systems and methods for local modulation of wnt signaling
BR112021021689A2 (pt) 2019-05-15 2022-03-22 Chugai Pharmaceutical Co Ltd Molécula de ligação a antígeno, composição farmacêutica, e método
CN112180094A (zh) * 2019-07-04 2021-01-05 上海东慈生物科技有限公司 Dkk1抑制剂在预防和/或治疗肿瘤恶病质与糖尿病伴随疾病中的应用
KR102192471B1 (ko) * 2019-10-18 2020-12-17 주식회사 인코스팜 탈모 완화 및 모발 성장을 촉진시키는 펩타이드 및 이를 포함하는 화장료 조성물
KR102494042B1 (ko) 2020-11-20 2023-02-07 주식회사 하울바이오 인간모유두세포의 성장을 촉진하는 항-dkk-1 항체 및 이의 용도
CN112592402B (zh) * 2020-12-02 2022-04-26 杭州奕安济世生物药业有限公司 抗dkk2抗体、包含该抗dkk2抗体的组合物及其用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7057017B2 (en) 1997-04-16 2006-06-06 Millennium Pharmaceuticals, Inc. Human dickkopf-related protein and nucleic acid molecules and uses therefor
US6391311B1 (en) 1998-03-17 2002-05-21 Genentech, Inc. Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
DE19747418C1 (de) 1997-10-27 1999-07-15 Deutsches Krebsforsch Inhibitor-Protein des wnt-Signalwegs
US7446181B2 (en) 1998-01-15 2008-11-04 Millennium Pharmaceuticals, Inc. Antibodies that bind human Dickkopf-1 proteins
NZ507435A (en) 1998-03-10 2003-12-19 Genentech Inc Novel polypeptides and nucleic acids with homology to cornichon
US6962797B2 (en) 1998-04-15 2005-11-08 Genentech, Inc. Nucleic acids encoding PRO615
US6344541B1 (en) 1998-09-25 2002-02-05 Amgen Inc. DKR polypeptides
US7193050B2 (en) 2000-02-18 2007-03-20 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6673549B1 (en) 2000-10-12 2004-01-06 Incyte Corporation Genes expressed in C3A liver cell cultures treated with steroids
AU2002306505B2 (en) * 2001-02-16 2007-02-15 Genentech, Inc. Treatment involving DKK-1 or antagonists thereof
AU2002342734B2 (en) * 2001-05-17 2007-07-26 Oscient Pharmaceuticals Corporation Reagents and methods for modulating Dkk-mediated interactions
US20040038860A1 (en) 2002-05-17 2004-02-26 Allen Kristina M. Reagents and methods for modulating dkk-mediated interactions
US7308364B2 (en) 2001-11-07 2007-12-11 The University Of Arkansas For Medical Sciences Diagnosis of multiple myeloma on gene expression profiling
US7371736B2 (en) 2001-11-07 2008-05-13 The Board Of Trustees Of The University Of Arkansas Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss
WO2003053215A2 (en) 2001-11-07 2003-07-03 The Board Of Trustees Of The University Of Arkansas Diagnosis prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling
US7894992B2 (en) 2001-11-07 2011-02-22 Board Of Trustees Of The University Of Arkansas Diagnosis and classification of multiple myeloma
US8124087B2 (en) 2002-12-05 2012-02-28 Board Of Trustees Of The University Of Arkansas Methods of controlling bone loss by inhibiting DKK1
US7459437B2 (en) 2002-12-05 2008-12-02 University Of Arkansas For Medical Sciences Molecular determinants of myeloma bone disease and uses thereof
US7642238B2 (en) 2002-12-05 2010-01-05 Shaughnessy John D Molecular determinants of myeloma bone disease and uses thereof
US7811750B2 (en) 2002-12-05 2010-10-12 Board Of Trustees Of The University Of Arkansas Molecular determinants of myeloma bone disease and use thereof
US20050084494A1 (en) 2003-05-21 2005-04-21 Darwin Prockop Inhibitors of Dkk-1
US8637506B2 (en) 2003-09-22 2014-01-28 Enzo Biochem, Inc. Compositions and methods for bone formation and remodeling
US8343922B2 (en) 2004-05-19 2013-01-01 Enzo Biochem, Inc. Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells
MX2007001221A (es) 2004-08-04 2007-03-23 Amgen Inc Anticuerpos para proteina dickkopf-1 (dkk-1).
AR060017A1 (es) * 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
WO2008070112A1 (en) 2006-12-06 2008-06-12 The Board Of Trustees Of The University Of Arkansas Overexpression of wnt ligands and treatment of lytic bone diseases
CA2677356A1 (en) 2007-02-08 2008-08-14 Zhiqiang An Antibodies specific for dkk-1
AR075989A1 (es) 2009-04-10 2011-05-11 Lilly Co Eli Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria

Also Published As

Publication number Publication date
PE20120475A1 (es) 2012-05-05
CN102666584A (zh) 2012-09-12
KR101471239B1 (ko) 2014-12-09
US8586721B2 (en) 2013-11-19
US20100291076A1 (en) 2010-11-18
TW201043247A (en) 2010-12-16
TWI411444B (zh) 2013-10-11
KR20120007078A (ko) 2012-01-19
US8338576B2 (en) 2012-12-25
AU2010246981A1 (en) 2011-12-08
RU2548817C2 (ru) 2015-04-20
NZ596274A (en) 2013-11-29
AU2010246981B2 (en) 2013-12-19
SG175881A1 (en) 2011-12-29
ZA201108310B (en) 2013-04-24
IL216304A0 (en) 2012-01-31
MX2011012039A (es) 2011-12-14
WO2010131185A1 (en) 2010-11-18
EP2430048A1 (en) 2012-03-21
JP2012526542A (ja) 2012-11-01
US20130071921A1 (en) 2013-03-21
CO6460768A2 (es) 2012-06-15
SA110310369B1 (ar) 2014-09-02
BRPI1010540A2 (pt) 2016-03-15
RU2011145435A (ru) 2013-06-20
CA2761696A1 (en) 2010-11-18

Similar Documents

Publication Publication Date Title
AR076668A1 (es) Anticuerpos especificos para dkk-1 y sus usos
BR112017003505A2 (pt) anticorpos e receptores de antígeno quiméricos específicos para cd19
BR112019004711A2 (pt) receptores de antígeno quiméricos compreendendo domínios de fibronectina tipo iii específicos para bcma e usos dos mesmos
CL2018001971A1 (es) Ror1 composiciones de anticuerpos y métodos relacionados
CO2018012415A2 (es) Proteínas de unión específica y usos de las mismas
MX2020001996A (es) Moleculas anti-cd137 y uso de estas.
UA115439C2 (uk) Гуманізоване антитіло, яке розпізнає альфа-синуклеїн
CL2019002566A1 (es) Anticuerpos anti-phf-tau y usos de estos.
EA201400625A1 (ru) Антитела против pd-l1 и их применение
MX2016007722A (es) Construcciones de anticuerpos de adn y metodo para utilizarlas.
PE20210665A1 (es) Anticuerpos contra mica y/o micb y sus usos
AR105490A2 (es) Generación y perfilado de anticuerpos terapéuticos derivados de hucal gold totalmente humanos específicos para cd38 humano
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
EA201170205A1 (ru) Антитела, нейтрализующие цитомегаловирус человека, и их применение
EA201492149A1 (ru) St2-антигенсвязывающие белки
MX391159B (es) Proteínas de unión al antígeno anti-tigit y métodos para usarlas
EA201690377A1 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
EA201792221A1 (ru) Антитела против сортилина и способы их применения
PE20141166A1 (es) Anticuerpos anti-angptl3 y usos de los mismos
PE20180249A1 (es) Anticuerpos neutralizadores anti-ccl20
CO6640289A2 (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
EA201892774A1 (ru) Антитела
MX2010009190A (es) Anticuerpos anti-c5ar humanizados.
EA201591113A1 (ru) Антитела против антигена 2 дендритных клеток крови и их применение
BR112014002817A2 (pt) Uso de um polipeptídeo p62, ou de um ácido nucleico que codifica p62

Legal Events

Date Code Title Description
FB Suspension of granting procedure